Medidata Honors 2017 Architects of Hope Award Winners at Medidata NEXT Global
November 10 2017 - 5:30PM
Business Wire
Over 1,000 Attendees Join Together to Recognize
the Success of Companies Leveraging the Industry Leading Medidata
Clinical Cloud® Platform to Accelerate Hope for Patients
Medidata (NASDAQ: MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced the winners of the second annual Architects of Hope
Awards. Four companies were recognized at the conclusion of the
Medidata NEXT Global customer and partner conference.
Medidata NEXT Global is the centerpiece of the largest annual
event series of its kind, which attracted over 3,000 attendees
across events in Basel, Berlin, London, Seoul, Shanghai, Tokyo and
New York.
Over 1,000 people attended Medidata NEXT Global which took place
this week. The three-day conference included 89 thought-provoking
sessions highlighting cutting-edge innovation within each phase of
the clinical development cycle. The event also featured eight
keynotes led by Medidata customers and CRO partners, including
senior executives and experts from Bristol-Myers Squibb, Celgene,
GlaxoSmithKline, Memorial Sloan Kettering, Worldwide Clinical
Trials, Accenture and more.
The 2017 Architects of Hope Award winners were selected for
their achievements in four categories.
2017 ARCHITECTS OF HOPE
AWARDS
BUILD AWARD - highlights relationships between and within
sponsors, CROs, and academic institutions that bring new insights
to clinical development to accelerate the development of new
medicines and hope for patients.
Award recipient - Memorial
Sloan Kettering Cancer Center
ACCELERATOR AWARD - recognizes a CRO who demonstrates a
shared commitment to helping sponsors drive clinical success and
through industry relationships, promotes the advancement and
acceleration of clinical trial execution. This is the first year
Medidata dedicated an award to a partner.
Award recipient - Worldwide
Clinical Trials
FOUNDATION AWARD - recognizes a customer who utilizes
technology to overcome challenges in clinical research and
development, and serves as an innovative thought-leader, helping to
build the foundation for the future of clinical trials.
Award recipient - Roche
Molecular Systems
DESIGN AWARD - recognizes a customer who uses technology
to overcome complex and challenging clinical trial implementation
issues, and shows measurable increases in operational and trial
efficiencies through innovative trial design.
Award recipient - Tesaro
Medidata also hosted the NEXT Hackathon during the conference,
providing cross-functional teams of business experts and developers
the opportunity to create new tools to showcase the power and
flexibility of the Medidata platform APIs. Team Chipper, placed
first in the 24-hour competition for creating a mobile application
for Pediatric PRO that layers gamification with an avatar
specifically designed for child-patient engagement. The project was
built on AppConnect and RaveX.
“We’re thrilled to work with forward-thinking life sciences
companies committed to driving better clinical outcomes and
advancing treatment options for patients through innovation and
technology,” said Tarek Sherif, Medidata CEO and founder. “We are
proud to recognize the achievements of our customers as they use
our solutions to tackle some of today’s most difficult-to-treat
diseases. We extend them all our sincere congratulations.”
As part of the program, Medidata NEXT hosted an Executive
Innovation Tour bringing together industry executives from across
the globe who visited a number of high tech companies in New York,
which are driving innovation in life sciences.
Medidata NEXT will kick off its 2018 season on March 7 in Basel,
Switzerland. More information, locations and dates can be found
here.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 950 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171110005615/en/
MedidataInvestor:Medidata SolutionsAnthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Medidata SolutionsErik Snider
, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2023 to Sep 2024